<< Conflicts of interest examined between doctors and medical industry, AARP and reform | Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Filipino | हिन्दी | Русский | Svenska | Polski

AGA Medical Holdings receives regulatory product approvals and licenses in China

Published on November 4, 2009 at 8:39 AM · No Comments

AGA Medical Holdings, Inc. (AGA Medical) (NASDAQ:AGAM) has received regulatory approvals and licenses in China for its AMPLATZER® PFO Occluder and AMPLATZER® Multi-Fenestrated Septal Occluder “Cribriform.”

The company has also received regulatory approval for its AMPLATZER® Vascular Plug II in China, and its license is pending. The company plans to make the products available through its distributor Abbott Vascular, a division of Abbott Laboratories, Inc.

“We see considerable opportunities in developing markets, such as China, and we are excited to expand our presence there,” said John Barr, president and chief executive officer of AGA Medical. “Today’s announcement demonstrates our ability to obtain product approvals in important markets, and we look forward to making AMPLATZER products more widely available.”

http://www.amplatzer.com/

Posted in: Device / Technology News

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading